Zebeth Media Solutions

Venture

Twitter is a startup again, I guess • ZebethMedia

Hello and welcome back to Equity, a podcast about the business of startups, where we unpack the numbers and nuance behind the headlines. Stocks are mixed around the world, notably lower in China on the back of some negative economic data, and down in the United States ahead of what is expected to be another rise in interest rates thanks to the Federal Reserve. Crypto prices have held onto recent gains. A busy weekend of Twitter leaks lead the news cycle. Precisely if, and if yes, how much, Twitter can charge for verified accounts to keep their badge is now a point of conversation. Other reports of development deadlines with termination held as a threat if they are not met are likely doing great things for staffer morale. It turns out that self-driving cars are still far away. I am crying. Startups Zebra Labs and Invygo raised money, showing that the global startup investment market has not frozen, and that there is still funding for more future-facing efforts like Zebra in the metaverse. Finally, we’re keeping close tabs on the Q4 venture capital cycle. If we don’t see a rebound soon, how many unicorns die? And that’s our show! More Wednesday! Equity drops at 7 a.m. PT every Monday and Wednesday, and at 6 a.m. PT on Fridays, so subscribe to us on Apple Podcasts, Overcast, Spotify and all the casts. ZebethMedia also has a great show on crypto, a show that interviews founders, one that details how our stories come together, and more!

6 reasons why you shouldn’t join an accelerator • ZebethMedia

Saba Karim is director of the startup pipeline at Techstars. As the head of startup pipeline at Techstars, I’ve been getting on calls with founders, attending events, speaking on stages like ZebethMedia’s Disrupt and hosting countless Twitter Spaces. Each time, I’ve been telling founders why they should join an accelerator. Now, I am changing things up and going to lay out six reasons you shouldn’t join an accelerator. If you only need funding You’re better off going to VCs, angel investors, crowdfunding, applying for grants or seeking venture debt. Accelerators usually take more (equity), because they provide more than just money. They give you funding and fundraising opportunities, mentorship and networks, workshops and usually a place to work. If you don’t need any of that, then you don’t need an accelerator. Accelerators are great because they’re a forcing mechanism to reach your most desired outcome by the end of the program, but no one is going to drag you out of bed every morning. Keep in mind that funding will solve your money problems, but it won’t solve everything else. You’ll still need to figure out how to acquire customers, find the best talent, build an incredible product, assemble a great advisory board and get to product-market fit. Do you just need funding? Lucky you. For crowdfunding, you can’t go wrong with Republic or WeFunder. For venture debt options, check out SVB or Mercury, and OpenGrants for, well, grants. To do customer development Customer development, also known as customer discovery or idea validation, is the notion of validating your startup idea. You don’t need an accelerator to tell you to talk to your customers. You should be doing it anyway. Otherwise, why are you building the thing you want to build? Yes, many accelerators accept companies at the idea stage, but it’s usually on the premise that primary or secondary research has been conducted to show you’re building something people have said they would use and/or pay for.

3 founders discuss how to navigate the nuances of early-stage fundraising • ZebethMedia

Fundraising isn’t a monolithic event but rather a series of meetings and pleasantries, each with their own vibe and nuance. Yet many pieces of fundraising advice to founders paint the process with a broad brush. We heard from three founders at ZebethMedia Disrupt last week: Amanda DoAmaral, co-founder and CEO of Fiveable; Arman Hezarkhani, founder of Parthean; and Sarah Du, co-founder of Alloy Automation, each of whom has raised in the extreme highs and lows of last 18 months. They spoke about navigating the process, what worked (and what didn’t) and how to customize your pitch to navigate the many subtleties of fundraising. For DoAmaral, it was important to spend time researching which investors may actually back her company. She said she’s had investors take meetings with her due to a warm intro despite having no actual intention to invest. “My co-founder and I got in a car and drove down to Tennessee thinking we’re gonna get this check. And this guy didn’t even trust me to like, be an attendee at this event. They’re not writing the check,” DoAmaral recalled. “People are not going to take me seriously if they’re not going to see me as someone that is their equal at all.” Du added that performing due diligence on potential backers beforehand is helpful, not only to find out whether they might actually invest in the company, but also if they will be good to work with. This is especially true for founders raising at the early stages who are looking at a long relationship ahead.

it’s an “open field” • ZebethMedia

If you’ve been closely following the progress of Open AI, the company run by Sam Altman whose neural nets can now write original text and create original pictures with astonishing ease and speed, you might just skip this piece. If, on the other hand, you’ve only been vaguely paying attention to the company’s progress and the increasing traction that other so-called “generative” AI companies are suddenly gaining and want to better understand why, you might benefit from this interview with James Currier, a five-time founder and now venture investor who cofounded the firm NFX five years ago with several of his serial founder friends. Currier falls into the camp of people following the progress closely — so closely that NFX has made numerous related investments in “generative tech” as he describes it, and it’s garnering more of the team’s attention every month. In fact, Currier doesn’t think the buzz about this new wrinkle on AI isn’t hype so much as a realization that the broader startup world is suddenly facing a very big opportunity for the first time in a long time. “Every 14 years,” says Currier, “we get one of these Cambrian explosions. We had one around the internet and ’94. We had one around mobile phones in 2008. Now we’re having another one in 2022.” In retrospect, this editor wishes she’d asked better questions, but I’m learning here, too. Excerpts from our chat follow, edited for length. You can listen to our longer conversation here. TC: There’s a lot of confusion about generative AI, including how new exactly it is, or whether it’s just become the latest buzzword. JC: I think what happened to the AI world in general is that we had a sense that we could have deterministic AI, which would help us identify the truth of something. For example, is that a broken piece on the manufacturing line? Is that an appropriate meeting to have? It’s where you’re determining something using AI in the same way that a human determines something. That’s largely what AI has been for the last 10 to 15 years. The other sets of algorithms in AI were more these diffusion algorithms, which were intended to look at huge corpuses of content and then generate something new from them, saying, ‘Here are 10,000 examples. Can we create the 10,001st example that is similar?’ Those were pretty fragile, pretty brittle, up until about a year and a half ago. [Now] the algorithms have gotten better. But more importantly, the corpuses of content we’ve been looking at have gotten bigger because we just have more processing power. So what’s happened is, these algorithms are riding Moore’s law — [with vastly improved] storage, bandwidth, speed of computation — and have suddenly become able to produce something that looks very much like what a human would produce. That means the face value of the text that it will write, and the face value of the drawing it will draw, looks very similar to what a human will do. And that’s all taken place in the last two years. So it’s not a new idea, but it’s newly at that threshold. That’s why everyone looks at this and says, ‘Wow, that’s magic.’ So it was compute power that suddenly changed the game, not some previously missing piece of tech infrastructure? It didn’t change suddenly, it just changed gradually until the point where our, the quality of its generation got to a point where it was meaningful for us. So the answer is generally no, the algorithms have been very similar. In these diffusion algorithms, they have gotten somewhat better. But really, it’s about the processing power. Then, about two years ago, the [powerful language model] GPT  came out, which was an on-premise type of calculation, then GPT3 came out where [the AI company Open AI] would do [the calculation] for you in the cloud; because the data models were so much bigger, they needed to do it on their own servers. You just can’t afford to do it [on your own]. And at that point, things really took a jump up. We know because we invested in a company doing AI-based generative games, including “AI Dungeon,” and I think the vast majority of all GPT-3’s computation was coming through “AI Dungeon” at one point. Does “AI Dungeon” then require a smaller team than another game-maker might?  That’s one of the big advantages, absolutely. They don’t have to spend all that money to house all that data, and they can, with a small group of people, produce tens of gaming experiences that all take advantage of that. [In fact] the idea is that you’re going to add generative AI to old games, so your non-player characters can actually say something more interesting than they do today, though you’re going to get fundamentally different gaming experiences coming out of AI into gaming, versus adding AI into the existing games. So a big change is in the quality? Will this technology plateau at some point? No, it will always be incrementally better. It’s just that the differences of the increments will be will be smaller over time because they’re already getting pretty good, But the other big change is that Open AI wasn’t really open. They generated this amazing thing, but then it wasn’t open and was very expensive. So groups got together like Stability AI and other folks, and they said, ‘Let’s just make open source versions of this.’ And at that point, the cost dropped by 100x, just in the last two or three months. These are not offshoots of Open AI. All this generative tech is not going to be built just on the Open AI GPT-3 model; that was just the first one. The open source community has now replicated a lot of their work, and they’re probably eight months behind, six months behind, in terms of quality. But it’s going to get there. And because the open source versions are a third or

With Musk’s purchase completed, NYSE will delist Twitter stock on Election Day • ZebethMedia

To get a roundup of ZebethMedia’s biggest and most important stories delivered to your inbox every day at 3 p.m. PDT, subscribe here. Happy Friday! Haje is enjoying some down time on the East Coast, so I am running solo. As you can see from the not-so-surprising move by Elon Musk last night and the sheer number of Twitter stories from our fabulous consumer tech team today, it has been all Twitter, all day. We promise to give you a little bit of that, of course, and a little of what else we’ve been working on. Let’s dive in, shall we?  — Christine The ZebethMedia Top 3 Flying the public coop: Now that Elon Musk owns Twitter, its days are numbered as a public company. In fact, Ivan writes, Twitter will be delisted on November 8 — voting day for the U.S. midterm elections. Caging the bird: Over to Europe, where just a few hours into actually owning Twitter, Musk already found himself on the wrong end of European Union officials, who corrected him after he tweeted about how free he thinks Twitter is now. Natasha L has more. Big Tweet Chief: Reports now say that Musk will take the CEO role for himself, Ivan writes, after he ousted Twitter’s four top executives, as reported by Amanda.  For more news on the blue bird, head down to the Big Tech Inc. section, where we have you covered. Startups and VC Unfortunately, the hits keep coming for 54gene, an African genomics startup focused on providing more African genetic material to pharmaceutical research — there is just 3% now, Tage reports. After some months of layoffs and a CEO exit, the company confirmed that it not only made yet another round of layoffs — this time of 100 people — but it also slashed its valuation by over $100 million. And we have three more for you: Robot riot: Galen Robotics has a new robot that will assist with ear, nose and throat surgeries. Oh, and it secured $15 million in new funding, Andrew reports. Follow the yellow brick road: Game studio Hidden Door is using narrative AI to turn fiction into immersive role-playing experiences, and Rebecca writes it is testing out “The Wizard of Oz.” Does anyone else use this word?: I was delighted to see that there is a company named Skidattl. The company is using augmented reality to show users what people are doing around them, in what Rebecca writes is “like a Bat-Signal for fun.” 5 ways biotech startups can mitigate risk to grow sustainably in the long run   Image Credits: jayk7 (opens in a new window) / Getty Images Thanks to R&D and clinical trials, life science startups have long lead times before they can bring their capital-intensive products to market. “But,” asks Omar Khalil, a partner at Santé Ventures, “what happens when the funding suddenly dries up?” In a guest post for TC+, he shares five strategies for biotech startups that are trying to stay warm through the winter ahead. “It’s still too early to know whether this is a short-term correction, or if it’s a new normal that will be maintained for the foreseeable future.” Three more from the TC+ team: ZebethMedia+ is our membership program that helps founders and startup teams get ahead of the pack. You can sign up here. Use code “DC” for a 15% discount on an annual subscription! Big Tech Inc. As promised, we have even more Twitter news for you to enjoy. As I write this, several of my colleagues hopped on Twitter Spaces to talk about all this. One of the latest bits of news from Taylor was that Elon Musk was forming a content moderation “council” to make certain decisions — for example, about account reinstatements for, cough, Donald Trump. Here’s two more: Catching you up on more earnings reports: And we have four more for you:

Fundraising beyond the Bay Area, web3 gaming, TDD prep checklist • ZebethMedia

In a previous era, aspiring journalists relocated to New York, would-be actors made pilgrimages to Hollywood, and plucky tech founders moved to the Bay Area so they could attract capital and talent. But San Francisco is no longer the center of the startup universe, and it hasn’t been for a while. Cities like Boulder, Detroit and Austin had emerging tech ecosystems long before the pandemic forced VCs to start taking pitches via Zoom, and social media has leveled the playing field when it comes to networking and PR. Full ZebethMedia+ articles are only available to membersUse discount code TCPLUSROUNDUP to save 20% off a one- or two-year subscription “We noticed a couple of years ago, in looking at our own analytics, that most of our deals were coming through Twitter,” said Elizabeth Yin, co-founder and general partner of Hustle Fund, last week at ZebethMedia Disrupt. “If I look at my portfolio, my companies that are active on Twitter actually do have an easier time raising money because investors feel like they know them.” Reporter Dominic-Madori Davis moderated a discussion with Yin, Mike Asem (founding partner of M25), and Accel partner Rich Wong that elicited suggestions for early-stage founders who don’t live in the 415 area code and spilled the tea about “the emerging markets on their radars.” If you’re interested in the entire conversation, there’s a link to a video at the end of the article. Keep an eye out for more recaps from TC Disrupt in the coming days. Thanks for reading, Walter ThompsonEditorial Manager, ZebethMedia+@yourprotagonist 5 tips for launching in a crowded web3 gaming market Image Credits: Chelsea Sampson (opens in a new window) / Getty Images Every online product requires some network effect, but gaming is unique: Without large, loyal and enthusiastic customers, there’s no way to build products that can be monetized. Play-to-earn games (P2E) are particularly susceptible to this problem, which is why “building a game that succeeds in the long term means developing monetization strategies that can weather market ebbs and flows,” says Corey Wilton, co-founder and CEO of Mirai Labs, the gaming studio behind Pegaxy. In this primer for P2E founders, Wilton shares suggestions for how to approach investors, explains why tokens are not a reliable fundraising vehicle and discusses the recent “shift toward Web 2.0 monetization.” A prep checklist for startups about to undergo technical due diligence Image Credits: Pixelimage (opens in a new window) / Getty Images On Tuesday, founder and CEO of codebase analytics company Sema, Matt Van Itallie, shared a guest post for founding teams who are about to begin technical due diligence before an investment or acquisition. On Wednesday, he followed up with a detailed checklist for C-level executives and senior managers responsible for helping VCs determine whether their “codebase is safe enough for investment.” Product roadmap Code quality Code, network and information security Intellectual property Development process Engineering team contributions DevOps Pitch Deck Teardown: The Palau Project’s $125k pre-seed deck Image Credits: Palau Project (opens in a new window) Fundraising takes many forms, but because pre-seed founders are so often coaxing money from family and friends to validate their ideas, it can raise the emotional stakes. To raise money for The Palau Project, an app that lets users find the environmental impact and nutritional benefits of packaged food, founder Jerome Cloetens put together a 22-slide deck with a $500,000 goal. In the end, the team raised just $125,000. Dear Sophie: How can early-stage startups improve their chances of getting H-1Bs? Image Credits: Bryce Durbin/ZebethMedia Dear Sophie, We have a stealth early-stage biotech startup. Do we qualify to petition a co-founder on STEM OPT for an H-1B in the lottery? Is it worth it or are there better alternatives? — Budding Biotech 3 VCs explain how founders can stand out when pitching Image Credits: Kelly Sullivan (opens in a new window) / Getty Images There’s a lot of wisdom in corny motivational writing. For instance, this quote by Will Durant, a historian and philosopher: We are what we repeatedly do. Excellence, then, is not an act, but a habit. A great pitch requires more than charm and storytelling skills: investors expect founders to understand their market and competitors, and help them prepare before the meeting begins. “I generally recommend having almost like a teaser version of the deck with enough data and information to give us a sense of where you are in terms of the journey of your company,” said Jomayra Herrera, a partner at Reach Capital. “Just enough information so that we come prepared to the meeting.” 5 ways biotech startups can mitigate risk to grow sustainably in the long run Image Credits: jayk7 (opens in a new window) / Getty Images Thanks to R&D and clinical trials, life science startups have long lead times before they can bring their capital-intensive products to market. “But,” asks Omar Khalil, a partner at Santé Ventures, “what happens when the funding suddenly dries up?” In a guest post for TC+, he shares five strategies for biotech startups that are trying to stay warm through the winter ahead. “It’s still too early to know whether this is a short-term correction, or if it’s a new normal that will be maintained for the foreseeable future.”

Latinx founders see VC funding drop as investors retreat from underrepresented cohorts • ZebethMedia

The latest Crunchbase data shows that Latinx-founded companies in the United States raised $250 million out of the $39.85 billion allocated in venture funds in the U.S. this Q3 — or about 0.63%.1 The Q3 sum is a sharp decrease from the $2.3 billion the cohort raised in Q3 last year and a dramatic decline from the $1.3 billion raise in Q2 this year. In total, 1.5% of all venture dollars so far in 2022 have been allocated to Latinx-founded companies, a drop from 2.5% last year, according to the Crunchbase analysis. The numbers are not surprising. Minorities and women overall are seeing dramatic dips in venture funding this year. ZebethMedia previously reported that Black founders raised $187 million this Q3, which meant, given historical data trends, the amount allocated to Latinx-founded companies wouldn’t be too far from that sum. Meanwhile, PitchBook found that female-founded companies have raised 1.9% of all venture funds so far this year, which is, again, a drop from the 2.4% the group raised last year. ZebethMedia noted before that investors tend to pull back toward their old networks to fund the founders who are familiar to them amid economic downturns — and those people tend to be white men. The somewhat encouraging news is that funding for early-stage Latinx-founded companies is on pace to exceed 2021’s total; much of the decline that we see in the above numbers came from a decrease in late-stage financing. The reality remains that women and minorities are not faring well right now when it comes to raising VC, and promises of change have dissipated. Last year, Latinx-founded U.S. companies raised $8.5 billion. Through the end of Q3 2022, that number stands at $2.7 billion, meaning it won’t even come close to passing last year’s record-breaking sum.

5 ways biotech startups can mitigate risk to grow sustainably in the long run • ZebethMedia

Omar Khalil is a partner at Santé Ventures, where he focuses primarily on biotechnology and medical technology companies. The unprecedented explosion of investment in life sciences over the past decade has resulted in incredible new therapies for patients, strong financial returns for companies and an overall increase in translational research, which is critical to advancing the next generation of therapies. It has also led to eye-popping levels of capital raised by early-stage companies, some of which were years away from entering the clinic with their first product. Naturally, a generous flow of financing generates excitement for everyone involved. Capital is the fuel that advances scientific and technological innovation, and it means a life science startup can create products that benefit the world at large. But what happens when the funding suddenly dries up? In the world of biotech, for example, it’s extremely capital intensive to develop multiple products that are all going through clinical trials simultaneously. The infrastructure needed to maintain these different programs can be too unwieldy to weather a financial drought. A better approach would be to focus on a lead program — a single product that they can take through various stages of development, ultimately leading to FDA approval. In fact, lead programs validate the value of an underlying platform, enabling companies to raise capital through licensing and partnerships. Founders shouldn’t let peer pressure or investor check size mandates dictate their financing strategy. There will always be ebbs and flows in funding, so here are five ways life science startups can optimize for success regardless of the economic climate. Don’t confuse successful fundraising with a successful company At the end of the day, fundraising is a means to an end. The mission for most life science startups is to improve patient outcomes. However, science is hard, and cash in the bank does not overcome the complexities of human biology. Plenty of companies have successfully raised significant amounts of capital but were never successful in developing a beneficial product, therapy or technology. While not a perfect proxy, the value at which a venture-backed company exits (through M&A or IPO) can be an indication of its success in developing a new product. However, there is practically no correlation between the amount of capital a company raises and its ultimate exit value. Since 2010, the R-squared between exit value and total invested capital — a measure of how correlated the two variables are — for all healthcare exits is a paltry 0.34. When you drill down to a correlation between the exit value and the amount of capital raised in a company’s Series A financing, it drops to a practically negligible value of 0.05, according to PitchBook. These statistics support the notion that just because a company raises significant amounts of capital (especially early on), there is no guarantee of a successful investment outcome. Founders shouldn’t let peer pressure or investor check size mandates dictate their financing strategy. Instead, focus on advancing your program through the key stages of technical and clinical development.

I regret to inform you that Elon has something to do with this • ZebethMedia

Hello and welcome back to Equity, a podcast about the business of startups, where we unpack the numbers and nuance behind the headlines. We hope that you are in good form this Friday, alive, well, and ready to rock. We certainly were. And in a change of pace, as our dear Mary Ann was off this week, the excellent Anita Ramaswamy joined Natasha Mascarenhas and Alex Wilhelm on the mics. (Theresa, as per usual, held down the production front!) What did we merry three get into? The following: We are back Monday for a spooky episode! Equity drops at 7 a.m. PT every Monday and Wednesday, and at 6 a.m. PT on Fridays, so subscribe to us on Apple Podcasts, Overcast, Spotify and all the casts. ZebethMedia also has a great show on crypto, a show that interviews founders, one that details how our stories come together, and more!

business and solar energy